EU grants marketing approval for children’s cancer immunotherapy drug

The drug ‘Dinutuximab beta Apeiron’ improves the survival and chances for cure in the severe paediatric cancer neuroblastoma

The European Commission has granted marketing authorisation for ‘Dinutuximab beta Apeiron’, an antibody-based immunotherapy of the rare paediatric cancer neuroblastoma. Thanks to the Vienna – based Biotech company Apeiron Biologics (Apeiron) patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of management and employees, academic institutions, Austrian private investors, business angels as well as public and private research initiatives.

The drug ‘Dinutuximab beta Apeiron’ improves the survival and chances for cure in the severe paediatric cancer neuroblastoma. The biological agent, an antibody, causes clinically relevant effects in both early and advanced stages of this aggressive disease. Based on the European Commission’s marketing authorisation Apeiron and its marketing partner EUSA Pharma will now be able to provide an immunotherapy for neuroblastoma in Europe and subsequently worldwide.